Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adenocarcinoma: early-phase trial registry
7 of 27 indexed Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 7 currently recruiting · #598 of 28,707 conditions by registered trial count
Adenocarcinoma: 27 US clinical trials tracked, 7 recruiting.
Adenocarcinoma is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition adenocarcinoma
OPEN 7 | RECR 26% | LATE 2 | EARLY 22 | RANK #598 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Hot Flashes (26% recruiting · 27 trials)
Adenocarcinoma lists 7 open slots (26% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adenocarcinoma is recruiting below its size-band peers.
7 of 27 indexed trials (25.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Adenocarcinoma trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 3 of 27 trials (11.1%). 22 distinct sponsors appear on at least one study for this condition label.
-
Most Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 27 trials that report a genuine target (sentinel values excluded). 20 of those (74.1%) plan for fewer than 100 participants.
-
Adenocarcinoma research is mostly interventional.
25 interventional and 2 observational studies make up this index (92.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02133196
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
NCT07259317
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Harry H Yoon
NCT04069273
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
University of Chicago
NCT04361708
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
NCT05922930
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Gulam Manji
NCT04543071
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Roberto Vargas
NCT05065736
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development
NCT04644770
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00911118
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics
NCT04660929
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
University of Kansas Medical Center
NCT03488667
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
NCT05273554
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Pfizer
NCT00140075
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis Pharmaceuticals
NCT00719264
EchoTip AcuCore Post-Market Clinical Study
Cook Research Incorporated
NCT06358001
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Pierian Biosciences
NCT00443196
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Pfizer
NCT00600821
Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery
Ohio State University Comprehensive Cancer Center
NCT01646697
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Pasi A. Janne, MD, PhD
NCT00137839
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
Ohio State University Comprehensive Cancer Center
NCT00201838
SBRT for Organ Confined Prostate Cancer
Northwell Health
NCT02653248
Cancer Vaccine Targeting Brachyury Protein in Tumors
National Cancer Institute (NCI)
NCT01519817
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
M.D. Anderson Cancer Center
NCT01365156
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.
Gary Onik MD
NCT03695835
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Swedish Medical Center
NCT00430261
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
NCT01161186
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Andrew Ko
NCT01383538
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 10 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adenocarcinoma page
27 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenocarcinoma condition card totals 27 registered trials; most-linked intervention Gemcitabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.